Assessment of the degree of violations of hemostasis parameters, rheology, markers of inflammation in patients with arterial hypertension and different risks of venous thromboembolic complications

The aim of the work is to investigate the parameters of hemostasis, electrical and viscoelastic parameters of red blood cells and markers of inflammation in persons suffering from arterial hypertension to determine the possibility of assessing the severity of hemorheological disorders.

Material and methods. The study included 203 patients (156 patients with arterial hypertension and 47 patients without hypertension). The parameters of hemostasis, markers of inflammation and red blood cells were studied.

Results. The possibilities of assessing the severity of hemorheological disorders in patients with arterial hypertension, based on the study of parameters: hemostasis, erythrocytes (by dielectrophoresis). In patients with hypertension, as the risk of venous thromboembolic complications increased, acceleration of leukocyte-platelet aggregation, increased fibrinogen level and decreased activity of XII-dependent fibrinolysis, which creates prerequisites for rheological disturbances, were revealed. The most accurate prediction of result according to severity of hemorheological disorders (differentiation moderate and expressed disorders from the lungs) is provided by such indicators of electric and viscoelastic parameters of erythrocytes, as the polarizability of red blood cells at a frequency of 106 Hz (AUC = 0,750 in), the speed of movement of cells to the electrodes (AUC = 0,746), deformation degree at a frequency of 5 × 105 Hz (AUC = 0,733), conductivity cell (AUC = 0,730), the generalized viscosity (AUC = 0,729), the index of aggregation of erythrocytes (AUC = 0,716), graduation according to the degree of strain at all frequencies (AUC = 0,716), generalized stiffness (AUC = 0,714), the deformation amplitude at frequency of 106 Hz (AUC = 0,711), the capacity of the cells (AUC = 0,693). The measure of specificity for different indices of erythrocytes is 75.4–99,3 % and a sensitivity of 84.1–98.6 %.

Conclusions. The study of the parameters of hemostasis, markers of inflammation, red blood cells allowed us to determine the key indicators for assessing the severity of hemorheological disorders in patients with arterial hypertension. The work was carried out within the framework of the budgetary theme under the State Assignment No. 121090800102-4.

1. Zhukov A.G., Mikhailova E.V., Muratov S.V., Karpenko V.Y. Specific features of the hemodynamic, rheological and bioenergetics indicators in weathersensitive patients with the arterial hypertension. RUDN Journal of Medicine, 2017; 4 (21): 425–431. (In Russ.)

2. Plotnikov M.B., Aliev O.I., Nosarev A.V., Shamanaev A.Y., Sidekhmenova A.V., Anfinogenova Y., Anishchenko A.M., Pushkina E.V. Relationship between arterial blood pressure and blood viscosity in spontaneously hypertensive rats treated with pentoxifylline. Biorheology, 2016; 2 (53): 93–107.

3. Chazova I.E., Ratova L.G., Boytsov S.A., Nebieridze D.V. Diagnostika i lechenie arterial’noy gipertenzii (Rekomendatsii Rossiyskogo meditsinskogo obshchestva po arterial’noy gipertonii i Vserossiyskogo nauchnogo obshchestva kardiologov). Systemic Hypertension, 2010; 3 (7): 5–26. (In Russ.)

4. Detterich J.A. Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy? Clin. Hemorheol. Microcirc., 2018; 68 (2-3): 173–186. doi: 10.3233/CH-189006

5. Podzolkov V.I., Bragina A.E., Osadchiy K.K. A fixeddose lisinopril + amlodipine + rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia. Terapevt. Arkh., 2017; 12 (89): 133–40. (In Russ.)

6. Shilov A.M., Knyazev S.A., Dulaeva M.S. Cardioselective β-blockers (bisoprolol) in the treatment of СHF in the practice of a primary care physician. RMJ, 2015; 10: 565. (In Russ.)

7. Ovchan H.O., Khomenko V.M., Andrushko I.I. et al. Experience and comparison of antihypertensive effect of ACE inhibitor spirapril and calcium antagonist amlodipinein standard and chronotherapeutic prescription mode. Wiad. Lek., 2017; 4 (70): 721–724.

8. Caprini J.A. Chapter 41 – Thrombotic risk assessment: A hybrid approach. In: The Vein Book. Ed. J.J. Bergan. Acad. Press, 2007. P. 359–367. doi:10.1016/B978-012369515-4/50044-2

9. Park Ch.S., Kim H.Y., Park H.-J. et al. Association between the JNC 7 classification of the stages of systolic hypertension and inflammatory cardiovascular risk factors. Korean Circ. J., 2007; 37: 623–629. doi: 10.4070/kcj.2007.37.12.623

10. Luther J.M., Gainer J.V., Murphey L.J. et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension, 2006; 48 (6): 1050–1057. doi: 10.1161/01.HYP.0000248135.97380.76

11. Chae C.U., Lee R.T., Rifai N., Ridker P.M. Blood pressure and inflammation in apparently healthy men. Hypertension, 2001; 38: 399–403. doi: 10.1161/01.hyp.38.3.399

12. Coles B., Fielding C.A., Rose-John S. et al. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin IIdependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol., 2007; 171: 315–325. doi: 10.2353/ajpath.2007.061078

13. Zhang W., Wang W., Yu H. et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension, 2012; 59 (1): 136–144. doi: 10.1161/HYPERTENSIONAHA.111.173328.

14. Guzik T.J., Hoch N.E., Brown K.A. et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med., 2007; 204 (10): 2449–2460. doi: 10.1084/jem.20070657

15. Huang B., Cheng Y., Usa K. et al. Renal tumor necrosis factor α contributes to hypertension in dahl saltsensitive rats. Sci. Rep., 2016; 6: 21960. doi: 10.1038/srep21960

16. Saveliev V.S., Chasov E.I., Gusev E.I., Kirienko A.I. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Flebologia. 2010; 2: 37. (In Russ.)

17. Generalov V.M., Kruchinina M.V., Durymanov A.G., Medvedev A.A., Safatov A.S., Sergeev A.N., Buryak G.A., Kurilovich S.A., Gromov A.A. Dielectrophoresis in the diagnosis of infectious and non-infectious diseases. Novosibirsk: Publishing «Tsaris», 2011. P. 172. (In Russ.)

18. Menshikov V.V. Clinical laboratory analytics. Vol. III. Private analytical technology in clinical laboratory. Mocsow: Labpress, 2000. P. 384. (In Russ.)

19. Kuznik B.I. Cellular and molecular mechanisms of regulation of the hemostasis system in health and disease. Chita: Express Publishing, 2010. P. 828. (In Russ.)

20. Kruchinina M.V., Gromov A.A., Generalov V.M. Laboratory control of primary hemostasis. Tutorial. Novosibirsk: Gross-master, 2017. 149 p. (In Russ.)

21. Litvinov R.I., Weisel J.W. Role of red blood cells in haemostasis and thrombosis. ISBT Sci. Ser., 2017; 12 (1): 176–183. doi: 10.1111/voxs.12331